Parasal
(Aminosalicylic acid)PreclinicalSmall molecule
Parasal is one of 31 small molecule programs targeting Pulmonary Tuberculosis. It is currently in Preclinical.
2
Indications
3
Total Trials
0
Active Trials
30
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
36 competitors in Pulmonary Tuberculosis
#DrugCompanyPhaseTrials
1Nydrazid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Priftin
SanofiApproved
Myambutol
VVA Greater Los Angeles Healthcare System
Approved
Calciferol
Jazz PharmaceuticalsApproved
Avelox
BayerPhase 3
Decadron
AAspen Global Incorporated
Approved
Rayos
RRoxane Laboratories
Approved
Kenalog
BBausch Health Americas, Inc.
Approved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Pulmonary Tuberculosis1 trial
A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000796·525 enrolled
Small Bowel Crohn's Disease1 trial
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
PARASAL
NDA NDA006811
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Aminosalicylic acid. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details